FDA approves inhalant for PAH

SILVER SPRING, Md. The Food and Drug Administration has approved an inhaled drug for treating pulmonary arterial hypertension.

United Therapeutics Corp. announced Thursday the approval of Tyvaso (treprostinil). The drug is used to increase the walking distance in patients with certain types of PAH.

“We are thrilled to have a fourth approval from the FDA for treatment of this serious cardio-pulmonary condition,” United Therapeutics’ chairman and CEO Martine Rothblatt said in a statement.